A randomized, open label, active controlled study of AMG 162 [denosumab] in subjects with advanced cancer currently being treated with intravenous bisphosphonates
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Denosumab (Primary) ; Pamidronic acid; Zoledronic acid
- Indications Advanced breast cancer; Bone resorption; Breast cancer; Cancer metastases; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours
- Focus Pharmacodynamics; Therapeutic Use
- 06 Jan 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 06 Jan 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.